AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial
Reuters
Published Jun 30, 2022 08:47
(Reuters) - AstraZeneca (NASDAQ:AZN) said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery.
Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in patients with non-small cell lung cancer, the Anglo-Swedish drugmaker said.
The interim result is a boost to the company's oncology efforts - a major area of focus - following disappointing data for Imfinzi earlier in the year in another area of therapy. (https://reut.rs/3nq1chi)
AstraZeneca added the trial would continue as planned to assess the additional main goal of event-free survival, and the interim data would be shared with health authorities globally.
Imfinzi belongs to the immunotherapy class of treatments, which boost the body's defences to fight cancer by using antibodies that block or bind to foreign substances in the body. The treatment generated $2.41 billion in 2021 sales.
"Engaging the immune response with Imfinzi both before and after surgery is an exciting new strategy," said Susan Galbraith, executive vice president of oncology R&D at AstraZeneca.
Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of the estimated 2.2 million new cases of the disease diagnosed each year worldwide, according to the World Health Organization.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.